Head Office
Level 1, 30-34 Hickson Rd, Millers Point, NSW 2000
P: 02 9298 3999 F: 02 9566 4686

Manufacturing & Human Resources
15 Garnet St, Carole Park QLD 4300

18th December 2023

Dear Healthcare Professional

Shortage of Dexamethasone Viatris (dexamethasone sodium phosphate) 4mg/mL vials Aust R 163200 and supply arrangement under Section 14 and 14A of the *Therapeutic Goods Act 1989*

The Australian registered medicine, DEXAMETHASONE VIATRIS 4mg/mL solution for injection AUST R 163200, sponsored by Alphapharm Pty Ltd (trading as Viatris), has been unavailable since 1st April 2022.

Alphapharm has been able to arrange supply of further quantities of this product to the market . under an approval granted by the Therapeutic Goods Administration (TGA) under section 14 and 14A of the *Therapeutic Goods Act 1989* until 1 August 2024.

The following batches have been released:

7608865 – Expiry 03/ 25

7608866 – Expiry 03/ 25

7608882 – Expiry 03/25

7608895 – Expiry 03/25

7608896 – Expiry 03/25

PBS Reimbursement

Dexamethasone Viatris 4mg/mL solution for injection AUST R 163200 is not listed for reimbursement on the PBS.

Adverse Event Reporting

Reporting any suspected adverse event is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with [section 14 and 14A approved medicine] should be reported by healthcare professionals and patients to:

- TGA at https://aems.tga.gov.au/; and/or
- Viatris on 1800 274 276 or by email medinfo_anz@viatris.com

Please forward this information to relevant staff members in your organisation.

For further information, please contact Viatris on 1800 274 276 or email ausalessupport@viatris.com.

Yours sincerely



Judy Bott
Institutional Business Manager
Alphapharm Pty Ltd (trading as Viatris)
DEX-2023-0019